|
|
SFX by Ex Libris Inc.
|
List of services to meet your request
|
|||||||||||||
|
|||||||||||||
© 2024 SFX by Ex Libris Inc. | Cookie Policy
CrossRef Omogočeno
![](https://beacon01.alma.exlibrisgroup.com/boom/apache_pb.gif?SRVR=adz.izum.si&IP=193.2.126.232&A=SFX&P=SFXMenu&S=sD8E0BC6C-36D7-11EF-8AE1-889985CE164B&I=39IZM&T=&OP=Display&O=html&O1=12648518&O2=2670000000385709&O3=&O4=summon.serialssolutions.com&O5=https%3A%2F%2Fadz.izum.si%2Fsfxlcl41%3Fctx_enc%3Dinfo%253Aofi%252Fenc%253AUTF-8%26ctx_ver%3DZ39.88-2004%26rfr_id%3Dinfo%253Asid%252Fsummon.serialssolutions.com%26rft.atitle%3D756%25E2%2580%2585First-in-human%252C%2520open-label%252C%2520multicenter%252C%2520phase%25201%2520clinical%2520study%2520to%2520evaluate%2520safety%252C%2520tolerability%252C%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520anti%2520Siglec-15%2520PYX-106%2520in%2520subjects%2520with%2520advanced%2520solid%2520tumors%26rft.au%3DGordon%252C%2520Michael%2520S%26rft.au%3DHenry%252C%2520Jason%26rft.au%3DPatel%252C%2520Sandip%2520P%26rft.au%3DSpira%252C%2520Alexander%2520I%26rft.date%3D2023-11-01%26rft.eissn%3D2051-1426%26rft.epage%3DA852%26rft.externalDBID%3DHAS_PDF_LINK%26rft.genre%3Darticle%26rft.issue%3DSuppl%25201%26rft.jtitle%3DJournal%2520for%2520immunotherapy%2520of%2520cancer%26rft.pub%3DBMJ%2520Publishing%2520Group%2520LTD%26rft.spage%3DA852%26rft.volume%3D11%26rft_id%3Dinfo%253Adoi%252F10.1136%252Fjitc-2023-SITC2023.0756%26rft_val_fmt%3Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal&O6=1-UNPAYWALL-getFullTxt-object,2-PUBMED_CENTRAL_JOURNALS-getFullTxt-object,3-DOAJ_DIRECTORY_OPEN_ACCESS_JOURNALS-getFullTxt-object,4-EZB-FREE-00999_FREELY_AVAILABLE_EZB_JOURNALS-getFullTxt-object,5-GFMER_FREE_MEDICAL_JOURNALS-getFullTxt-object,6-PROQUEST_CENTRAL-getFullTxt-object,7-ROAD_DIRECTORY_OF_OPEN_ACCESS_SCHOLARLY_RESOURCES-getFullTxt-object,8-COBIB_SI_LCL-getHolding-object,9-DOI-getDOI-object,10-ELSEVIER_SCOPUS_FIS_LCL-getAbstract-object,11-REFWORKS_EXPORT_TOOL-getReference-object,12-SHERPA_RoMEO_LCL-getWebService-object,13-GOOGLE_BOOK_SEARCH-getWebSearch-object,14-GOOGLE_SCHOLAR_FREE-getWebSearch-object,15-WWW_SEARCH_ENGINES_FREE-getWebSearch-object&O7=0.942511&O8=N&O9=<ctx:context-object identifier="urn:sfxstat:12648518-sD8E0BC6C-36D7-11EF-8AE1-889985CE164B" timestamp="2024-06-30T13:57:01Z" xmlns:ctx="info:ofi/fmt:xml:xsd:ctx">
<ctx:referent>
<ctx:identifier>urn:sfxid:2670000000385709</ctx:identifier>
<ctx:metadata-by-val>
<ctx:format>info:ofi/fmt:xml:xsd:journal</ctx:format>
<ctx:metadata>
<jnl:journal xmlns:jnl="info:ofi/fmt:xml:xsd:journal">
<jnl:atitle>756 First-in-human, open-label, multicenter, phase 1 clinical study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of anti Siglec-15 PYX-106 in subjects with advanced solid tumors</jnl:atitle>
<jnl:jtitle>Journal for Immunotherapy of Cancer</jnl:jtitle>
<jnl:date>2023-11-01</jnl:date>
<jnl:spage>A852</jnl:spage>
<jnl:epage>A852</jnl:epage>
<jnl:volume>11</jnl:volume>
<jnl:issue>Suppl 1</jnl:issue>
<jnl:genre>article</jnl:genre>
<jnl:eissn>2051-1426</jnl:eissn>
<jnl:language>eng</jnl:language>
<jnl:authors></jnl:authors>
</jnl:journal>
</ctx:metadata>
</ctx:metadata-by-val>
</ctx:referent>
<ctx:requester>
<ctx:identifier>urn:ip:ca12aa2374c1314cc7d91992c63fd4a847376db6</ctx:identifier>
<ctx:identifier>urn:UUID:sD8E0BC6C-36D7-11EF-8AE1-889985CE164B</ctx:identifier>
</ctx:requester>
<ctx:referrer>
<ctx:identifier>info:sid/summon.serialssolutions.com</ctx:identifier>
</ctx:referrer>
<ctx:service-type>
<ctx:metadata-by-val>
<ctx:format>info:ofi/fmt:xml:xsd:svcList</ctx:format>
<ctx:metadata>
<svc:svcList xmlns:svc="http://www.exlibrisgroup.com/schema/info:ofi/fmt:xml:xsd:sch_svc"></svc:svcList>
</ctx:metadata>
</ctx:metadata-by-val>
</ctx:service-type>
<ctx:resolver>
<ctx:identifier>https://adz.izum.si/sfxlcl41</ctx:identifier>
</ctx:resolver>
</ctx:context-object>
&)